Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisantrene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | NQO1 | P15559 | 1/20 | 0.97 |
| ▸ | DRD1 | P21728 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.97 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.97 |
| ▸ | HTR6 | P50406 | 1/20 | 0.61 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisantrene SCHEMBL17819004 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL17819003 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL4773 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL29665174 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL29398210 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL8906393 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL7207049 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL7472 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL1649622 | 0.97 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| SCHEMBL23323322 | 0.92 | ADRA2A (0.86) | ADRA2AADRA1ACHRM2HTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4516305-A1 | METHOD AND COMPOSITION FOR PREVENTING OR TREATING MYOPIA | Tsubota Laboratory, Inc. (JP) | 2025-03-05 | — | — | EP | claimed |
| WO-2024092210-A1 | TARGETING THE M6A MRNA DEMETHYLASE FTO | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-05-02 | — | — | WO | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| WO-2019073296-A1 | LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR ANALOGS THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-04-18 | — | — | WO | claimed |
| WO-2026073303-A1 | PHARMACEUTICAL COMPOSITIONS SUITABLE FOR INTRAVENOUS ADMINISTRATION | RACE ONCOLOGY LTD (AU) | 2026-04-09 | — | — | WO | disclosed |
| US-20250262167-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-08-21 | — | — | US | disclosed |
| US-20250186438-A1 | TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA | RACE ONCOLOGY LTD (AU) | 2025-06-12 | — | — | US | disclosed |
| WO-2025089394-A1 | METHOD AND COMPOSITION FOR PREVENTING OR TREATING MYOPIA | 株式会社坪田ラボ | 2025-05-01 | — | — | WO | disclosed |
| EP-4516305-A1 | METHOD AND COMPOSITION FOR PREVENTING OR TREATING MYOPIA | Tsubota Laboratory, Inc. (JP) | 2025-03-05 | — | — | EP | disclosed |
| US-20250025445-A1 | METHOD OF CARDIOPROTECTION | RACE ONCOLOGY LTD. (AU) | 2025-01-23 | — | — | US | disclosed |
| WO-2005121341-A1 | TUMOR SPECIFIC ANTIBODY | VIVENTIA BIOTECH INC. (CA) | 2005-12-22 | — | — | WO | disclosed |
| WO-2004096271-A1 | METHODS FOR TREATING CANCER USING AN IMMUNOTOXIN | ZANGEMEISTER-WITTKE UWE (CH) | 2004-11-11 | — | — | WO | disclosed |
| EP-0214501-B1 | EMULSION COMPOSITIONS FOR ADMINISTRATION OF SPARINGLY WATER SOLUBLE IONIZABLE BASIC HYDROPHOBIC DRUGS | AMERICAN CYANAMID COMPANY (US) | 1992-09-23 | — | — | EP | disclosed |
| EP-0215313-B1 | EMULSION COMPOSITIONS FOR THE PARENTERAL AND/OR ORAL ADMINISTRATION OF SPARINGLY WATER SOLUBLE IONIZABLE HYDROPHOBIC DRUGS | AMERICAN CYANAMID COMPANY (US) | 1992-07-29 | — | — | EP | disclosed |
| US-4816247-A | FOR INJECTIONS | AMERICAN CYANAMID COMPANY (US) | 1989-03-28 | — | — | US | disclosed |
| US-4784845-A | FAT EMULSIONS WITH BENZYL ALCOHOL FOR DRUGS | AMERICAN CYANAMID COMPANY (US) | 1988-11-15 | — | — | US | disclosed |
| EP-0214501-A2 | Emulsion compositions for administration of sparingly water soluble ionizable basic hydrophobic drugs | AMERICAN CYANAMID COMPANY (US) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025445-A1 | METHOD OF CARDIOPROTECTION | TNNI3, TNNT2, FABP3 | ADRA2A 202/4885ADRA1A 161/4885CHRM2 1190/4885 |
| US-20250186438-A1 | TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA | VHL, RCC2, PBRM1 | ADRA2A 3917/4885ADRA1A 3597/4885CHRM2 4869/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | ADRA2A 1586/4885ADRA1A 1146/4885CHRM2 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.